Table 1B.
Detailed clinical data of the 14 MuSK-MG patients.
| Patient number | 8 | 9 | 10 | 11 | 12 | 13 | 14 |
|---|---|---|---|---|---|---|---|
| Sex | Female | Male | Female | Female | Female | Male | Female |
| Onset age (years) | 64 | 51 | 62 | 55 | 50 | 32 | 29 |
| MuSK Ab titer (U/ml) | 1.08 | 1.20 | >12.00 | 5.90 | 5.18 | 1.40 | >12.00 |
| Disease duration (months) | 4 | 2 | 54 | 135.6 | 3 | 70 | 1 |
| Onset symptom | Ptosis, diplopia | Ptosis | Diplopia | Ptosis, diplopia | Diplopia | Ptosis, diplopia | Ptosis, dysphagia |
| Tongue muscle atrophy | No | No | No | No | No | No | No |
| Jolly test | Positive | Positive | Positive | Negative | Negative | Positive | Positive |
| Time from onset to involvement of other muscle groups (months) | 3.5 | 1.5 | 3 | 132 | 7 | 6 | 1 |
| Most severe Osserman classification | IIb | IIb | IV | IIb | IIa | IIb | IIb |
| Maximum QMG scores | 14 | 11 | 22 | 12 | 4 | 20 | 13 |
| Time from onset to the peak (months) | 4 | 2 | 54 | 135.6 | 7 | 7 | 1 |
| Number of myasthenic crisis | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Neostigmine trial | Positive | Positive | Negative | Negative | Positive | Positive | Positive |
| Cholinergic side effect | No | No | Yes | Yes | No | No | No |
| Decrement on RNS (3 Hz) | Not done | No | Yes | Yes | Yes | Yes | Yes |
| Thymus CT scan/pathology | Normal | Normal | Normal | Normal | Bronchogenic cyst | Normal | Normal |
| TG/TPO Ab | Yes | Yes | Yes | Yes | No done | No done | No done |
| Other AD | Psoriasis | Allergic dermatitis | Without | Without | Without | Without | Without |
| Intravenous immunoglobulin | No | No | Yes | Yes | No | No | Yes |
| Glucocorticoid | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Tacrolimus | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Pyridostigmine bromide | 60 mg tid | 60 mg tid | No | No | 60 mg tid | 60 mg tid | 60 mg tid |
| Follow-up time (months) | 3 | 3 | 3 | 12 | 12 | 12 | 18 |
| QMG scores after treatment | 7 | 3 | 10 | 2 | 2 | 4 | 4 |
| Prognosis | Markedly effective | Markedly effective | Markedly effective | Basically cured | Markedly effective | Basically cured | Markedly effective |
MuSK-Ab (U/ml) (cut-off >0.40); QMG, quantitative myasthenia gravis; tid, three times a day; TG Ab, thyroglobulin antibody; TPO Ab, thyroid peroxidase antibody; AD, autoimmune disease; RNS, repetitive nerve stimulation.